Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gentamycin + ornidazole is a combination drug consisting of two active pharmaceutical ingredients: gentamicin, an aminoglycoside antibiotic, and ornidazole, a nitroimidazole antimicrobial. Gentamicin acts by binding to the 30S subunit of bacterial ribosomes, inhibiting protein synthesis and leading to bacterial cell death. It is primarily effective against aerobic Gram-negative bacteria. Ornidazole works by disrupting DNA synthesis in anaerobic bacteria and protozoa through reduction of its nitro group within microbial cells, resulting in cell death. This combination is used for the prophylaxis and treatment of mixed aerobic-anaerobic infections—such as those encountered in intra-abdominal surgeries (e.g., appendectomy or caesarean section)—where both Gram-negative aerobes and anaerobes are likely pathogens[1][2]. The combination leverages the complementary spectra of activity to provide broad coverage against common surgical site pathogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gentamycin + ornidazole.